Cy­nata signs MoU with US biotech com­pany

BioSpectrum (Asia) - - Company News -

Cy­nata Ther­a­peu­tics has signed a Mem­o­ran­dum of Un­der­stand­ing (MoU) with Celu­lar­ity Inc., a USbased biotech com­pany fo­cus­ing on re­gen­er­a­tive cells and tis­sues. Ac­cord­ing to the MoU, Celu­lar­ity will con­duct a com­mer­cial eval­u­a­tion of Cy­nata’s patented Cymerus pro­duc­tion method, in or­der to gauge its ef­fec­tive­ness when com­bined with Celu­lar­ity’s pro­pri­etary ther­a­peu­tic stem cell tech­nol­ogy. Cel­lu­lar­ity is cur­rently de­vel­op­ing ways to har­ness cells from the post­par­tum pla­centa to ad­dress se­ri­ous and life-threat­en­ing dis­eases; and util­is­ing strate­gic as­sets con­trib­uted from Cel­gene Cor­po­ra­tion, Sor­rento Ther­a­peu­tics, United Ther­a­peu­tics and Hu­man Longevity, Inc. Aus­tralian stem cell and re­gen­er­a­tive medicine com­pany Cy­nata’s pro­pri­etary Cymerus tech­nol­ogy ad­dresses a crit­i­cal short­com­ing in ex­ist­ing meth­ods of pro­duc­tion of mes­enchy­mal stem cells (MSCs) for ther­a­peu­tic use, which is the abil­ity to achieve eco­nomic man­u­fac­ture at com­mer­cial scale.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.